Entact Bio

Entact Bio

生物技术研究

Watertown,Massachusetts 2,540 位关注者

Creating new medicines by enhancing protein function

关于我们

Entact Bio is developing a novel class of precision medicines that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitylase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has built its proprietary Encompass? platform to create enhancement-targeting chimeric (ENTAC?) medicines. ENTACs leverage the natural ability of DUBs to regulate and enhance protein function. By harnessing the power of DUBs, Entact is expanding the universe of treatable diseases and creating new options for patients who are underserved by current therapeutic modalities.

网站
https://entactbio.com
所属行业
生物技术研究
规模
11-50 人
总部
Watertown,Massachusetts
类型
私人持股

地点

Entact Bio员工

动态

相似主页

融资

Entact Bio 共 2 轮

上一轮

未知

US$40,321,700.00

Crunchbase 上查看更多信息